D.A. Davidson & CO. Has $12.91 Million Holdings in Bristol-Myers Squibb Co (BMY)

D.A. Davidson & CO. lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 0.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 207,967 shares of the biopharmaceutical company’s stock after selling 1,519 shares during the period. D.A. Davidson & CO.’s holdings in Bristol-Myers Squibb were worth $12,911,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Cypress Capital Management LLC WY lifted its position in shares of Bristol-Myers Squibb by 154.7% in the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,160 shares during the last quarter. CSat Investment Advisory L.P. acquired a new stake in shares of Bristol-Myers Squibb in the second quarter worth about $113,000. Landaas & Co. WI ADV acquired a new stake in shares of Bristol-Myers Squibb in the second quarter worth about $131,000. Selective Wealth Management acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth about $184,000. Finally, LFA Lugano Financial Advisors SA lifted its position in shares of Bristol-Myers Squibb by 85.8% in the third quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 1,481 shares during the last quarter. 72.90% of the stock is owned by institutional investors.

NYSE BMY opened at $52.93 on Friday. Bristol-Myers Squibb Co has a twelve month low of $46.94 and a twelve month high of $70.05. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock has a market cap of $86.39 billion, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 1.48 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. As a group, analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 3.02%. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.

A number of analysts have weighed in on BMY shares. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Friday, October 5th. SunTrust Banks reissued a “buy” rating and set a $67.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. Barclays boosted their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Friday, October 12th. Credit Suisse Group reissued a “hold” rating and set a $61.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Finally, Morgan Stanley cut their price objective on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, November 6th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $61.84.

ILLEGAL ACTIVITY NOTICE: This report was first posted by WKRB News and is the property of of WKRB News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.wkrb13.com/2018/11/25/d-a-davidson-co-has-12-91-million-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Read More: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply